IRIS - Res&Arch Institutional Research Information System - Research & Archive

PORCELLATI, Francesca
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.195
EU - Europa 1.829
AS - Asia 533
OC - Oceania 14
AF - Africa 3
Continente sconosciuto - Info sul continente non disponibili 3
SA - Sud America 2
Totale 4.579
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.184
IE - Irlanda 385
IT - Italia 345
SE - Svezia 335
UA - Ucraina 311
SG - Singapore 165
HK - Hong Kong 138
CN - Cina 115
FI - Finlandia 108
RU - Federazione Russa 98
DE - Germania 81
VN - Vietnam 77
GB - Regno Unito 52
FR - Francia 30
CZ - Repubblica Ceca 19
AT - Austria 18
TR - Turchia 13
AU - Australia 12
CH - Svizzera 12
BE - Belgio 10
PL - Polonia 7
UZ - Uzbekistan 7
CA - Canada 6
RO - Romania 6
IN - India 5
MX - Messico 5
NL - Olanda 5
JP - Giappone 4
EU - Europa 3
GR - Grecia 3
KR - Corea 3
BD - Bangladesh 2
BR - Brasile 2
BW - Botswana 2
EE - Estonia 2
ID - Indonesia 2
LB - Libano 2
NZ - Nuova Zelanda 2
CI - Costa d'Avorio 1
IM - Isola di Man 1
LU - Lussemburgo 1
Totale 4.579
Salva come PNG Salva come JPEG
Città #
Chandler 474
Dublin 385
San Mateo 224
Boardman 174
Jacksonville 159
Hong Kong 137
Singapore 117
Altamura 112
Medford 109
Princeton 109
Wilmington 92
Lawrence 80
Ann Arbor 79
Perugia 77
Dong Ket 76
Andover 53
Beijing 38
Des Moines 38
Rome 33
Saint Petersburg 27
Helsinki 26
Woodbridge 23
Norwalk 21
Falls Church 20
Ashburn 17
Los Angeles 17
Amelia 15
Brno 14
Izmir 13
New York 13
Brussels 10
Moscow 10
Vienna 9
Milan 8
San Paolo di Civitate 8
Auburn Hills 7
Redmond 7
Fremont 6
Bucu 5
Melbourne 5
Chicago 4
Dallas 4
Houston 4
Olomouc 4
Terni 4
Athens 3
Corridonia 3
Den Haag 3
Guangzhou 3
Lappeenranta 3
Occhiobello 3
Redwood City 3
San Diego 3
Seoul 3
Shanghai 3
Surrey 3
Tappahannock 3
Torino 3
Treviso 3
Verona 3
Auckland 2
Bari 2
Bologna 2
Brendola 2
Catania 2
Dhaka 2
Fairfield 2
Frankfurt Am Main 2
Gaborone 2
Hyderabad 2
Jakarta 2
Lambeth 2
Lausanne 2
Leawood 2
Leipzig 2
León 2
Manassas 2
Nürnberg 2
Osoppo 2
Padova 2
Perth 2
Pisa 2
Plaistow 2
Plymouth 2
San Giuliano Terme 2
Selargius 2
Spring 2
Swansea 2
Tallinn 2
Toronto 2
Torre Del Greco 2
Varese 2
Abidjan 1
Alexandria 1
Amsterdam 1
Belo Horizonte 1
Berlin 1
Brisbane 1
Cepagatti 1
Clifton 1
Totale 2.984
Salva come PNG Salva come JPEG
Nome #
Ipoglicemia da iperinsulinismo organico: un caso di nesidioblastosi dell’adulto. 158
Different brain responses to hypoglycemia induced by equipotent doses of long-acting insulin analog detemir and human regular insulin in humans 114
Adrenaline vs glucagon in the primacy of glucose counterregulation 99
Administration of neutral protamine Hagerdon insulin at bedtime versus with dinner in type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control. A randomized, controlled trial. 94
Hypoglycemia 78
Portal vein glucose sensors do not play a major role in modulating physiological responses to insulin-induced hypoglycemia in humans. 75
Effect of the amino acid alanine on glucagon secretion in non-diabetic and type 1 diabetic subjects during hyperinsulinaemic euglycaemia, hypoglycaemia and post-hypoglycaemic hyperglycaemia. 72
Administration of Neutral Protamine Hagedorn insulin at bedtime versus dinner in Type 1 diabetes mellitus to avoid nocturnal hypoglycemia and improve control: a randomized, controlled trial. 71
EPIDEMIOLOGICAL SURVEY FOR THE DETECTION OF NON–TRAUMATIC LOWER EXTREMITY AMPUTATIONS IN DIABETIC PATIENTS IN THE UMBRIA REGION (ITALY). 67
EFFECT OF PYRIDOXAL 5'-PHOSPHATE AND VALPROICACID ON PHOSPHOLIPID SYNTHESIS INNEUROBLASTOMA NA 66
Fasting insulin has a stronger association with an adverse cardiometabolic risk profile than insulin resistance: the RISC study. 66
Short-term effects of the long-acting insulin analog detemir and human insulin on plasma levels of insulin-like growth factor-I and its binding proteins in humans. 66
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes: the role of insulin analogs 64
Uso dell’analogo ad azione rapida lispro con l’analogo ad azione ritardo glargine nel trattamento intensivo del T1DM 63
Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. 63
Cognitive function in hypoglycaemia 60
Comparison of pharmacokinetics and-dynamics of the long-acting insulin analogs glargine and detemir at steady state in type 1 diabetes mellitus: a double-blind, randomized, cross-over study. 60
Pivotal role of timely basal insulin replacement after metformin failure in sustaining long-term blood glucose control at a target in Type 2 diabetes. 58
Body weight, not insulin sensitivity or secretion, may predict spontaneous weight changes in nondiabetic and prediabetic subjects: the RISC study. 57
Intensive replacement of basal insulin in patients with type 1 diabetes given rapid-acting analogue at mealtime. A three month comparison between administration of NPH insulin four times daily and glargine insulin at dinner or bedtime. 56
A novel surrogate index for hepatic insulin resistance. 54
Counterregulatory hormone and symptom responses to insulin-induced hypoglycaemia in the postprandial state in humans 53
Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes. 53
Counterregulatory hormone and symptom responses to insulin-induced hypoglycemia in the postprandial state in humans 52
Circulating palmitoleic acid is an independent determinant of insulin sensitivity, beta cell function and glucose tolerance in non-diabetic individuals: a longitudinal analysis 52
Plasma sCD36 is associated with markers of atherosclerosis, insulin resistance and fatty liver in a nondiabetic healthy population. 52
Awareness, identification and prevention of insulin injection-associated lipodystrophies 52
Differential Effects of Adiposity on Pharmacodynamics of Basal Insulins NPH, Glargine, and Detemir in Type 2 Diabetes mellitus. 51
Shift of glycaemic thresholds for cognitive function in hypoglycaemia unawareness in humans. 51
Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro 51
null 49
Influence of the ACE gene insertion/deletion polymorphism on insulin sensitivity and impaired glucose tolerance in healthy subjects. 49
Pharmacokinetics and pharmacodynamic of therapeutic dose of basel insulins NPH, Glargine and Detemir after one week of daily administration at bedtime in Type 2 daibates: a randomized, cross-over study. 49
Effect of cigarette smoking and of a transdermal nicotine delivery system on glucoregulation in type 2 diabetes mellitus 49
Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes 49
Intensive replacement of basal insulin in patients with Type 1 diabetes mellitus given rapid-acting insulin analogue at meal-time: a three-month comparison between administration of NPH four times daily and glargine insulin at dinner or bedtime. 48
Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. 48
Pharmacokinetics and pharmacodynamics of the long-acting insulin analog glargine after 1 week of use compared with its first administration in subjects with type 1 diabetes. 47
Glucagon: the effects of its excess and deficiency on insulin action 47
Responses to hypoglycemia in diabetic autonomic neuropathy. 47
Effect of oral amino acids on counterregulatory responses and cognitive function during insulin-induced hypoglycemia in nondiabetic and type 1 diabetic people. 46
Quando “i conti non tornano” (Caso clinico) G It Diabetol Metab 26:172-175 45
Alternate splicing in human Na+-MI cotransporter gene yelds differentially regulated trasport isoforms 45
Insulin therapy and hypoglycemia: the size of the problem 43
Hyperglycemia, Both Chronic and in Short-Term Peaks, Results in Rapid Increase of Expression of Monocyte Inducible Cyclooxygenase (COX-2) in Subjects with T2DM 43
Influence of Apolipoproteins on the Association Between Lipids and Insulin Sensitivity: A cross-sectional analysis of the RISC Study 43
Comparative Effectiveness of Switching From First-Generation Basal Insulin to Glargine 300 U/ml or Degludec 100 U/ml in Type 1 Diabetes: The RESTORE-1 Study 43
Evaluation of the accuracy of a microdialysis-based glucose sensor during insulin-induced hypoglycemia, its recovery, and post-hypoglycemic hyperglycemia in humans. 42
Liver enzymes are associated with hepatic insulin resistance, insulin secretion, and glucagon concentration in healthy men and women. 42
Pharmacokinetics, pharmacodynamics, and modulation of hepatic glucose production with insulin glargine U300 and glargine U100 at steady state with individualized clinical doses in type 1 diabetes 42
L’ipoglicemia silente nella pratica clinica quotidiana: come diagnosticarla, gestirla e prevenirla 42
Greater Suppression of Glucagon, Lipolysis, and Ketogenesis with Insulin Glargine U300 as Compared with Glargine U100 in Type 1 Diabetes Mellitus 41
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 40
Mechanisms of arterial hypotension after therapeutic dose of subcutaneous insulin in diabetic autonomic neuropathy. 40
Low levels of unmodified insulin glargine in plasma of people with type 2 diabetes requiring high doses of basal insulin 40
Mechanisms of insulin resistance after insulin-induced hypoglycemia in humans: the role of lipolysis. 39
Recovery and prevention of hypoglycaemia unawareness in Type 1 diabetes mellitus 39
PHARMACOKINETIC AND PHARMACODYNAMIC HEAD-TO-HEAD COMPARISON OF CLINICAL, EQUIVALENT DOSES OF INSULIN GLARGINE 300 U/ML AND INSULIN DEGLUDEC 100 U/ML IN TYPE 1 DIABETES 39
Metabolism of insulin glargine after repeated daily subcutaneous injections in subjects with type 2 diabetes. 38
Thirty years of research on the dawn phenomenon: lessons to optimize blood glucose control in diabetes. 38
Glargine metabolism over 24 h following its subcutaneous injection in patients with type 2 diabetes mellitus: A dose–response study 38
Ricoveri per ipoglicemia grave in soggetti con diabete mellito di tipo 2: impatto clinico e costi sanitari 38
Superiority of insulin analogues versus human insulin in the treatment of diabetes mellitus. 37
INSULIN SENSITIVITY IN TYPE 2 DIABETIC PATIENTS IS DIFFERENT BETWEEN GLUCOSE AND PROTEIN METABOLISM 37
[Usefulness of plantar pressure measurement for the prevention and treatment of neuropathic diabetic foot]. 37
Pharmacokinetics and pharmacodynamics of NPH insulin in type 1 diabetes: The Importance of appropriate resuspension before subcutaneous injection 37
Prevention of hypoglycemia while achieving good glycemic control in type 1 diabetes mellitus. 36
Effect of sedentary behaviour and vigorous physical activity on segment-specific carotid wall thickness and its progression in a healthy population 35
Obesity and carotid artery remodeling 34
Insulin sensitivity and beta-cell function in the offspring of type 2 diabetic patients: impact of line of inheritance. 33
Pharmacokinetics and pharmacodynamics of basal insulins. 33
Insulin sensitivity and carotid intima-media thickness: relationship between insulin sensitivity and cardiovascular risk study. 33
The effect of menopause on carotid artery remodeling, insulin sensitivity, and plasma adiponectin in healthy women 33
ACE2 and SARS-CoV-2 Infection: Might GLP-1 Receptor Agonists Play a Role? 33
Natural history and physiological determinants of changes in glucose tolerance in a non-diabetic population: the RISC Study. 32
null 32
One hour post-load plasma glucose and 3 year risk of worsening fasting and 2 hour glucose tolerance in the RISC cohort 32
Body composition and common carotid artery remodeling in a healthy population 31
Gamma-glutamyltransferase, arterial remodeling and prehypertension in a healthy population at low cardiometabolic risk 30
Impact of family history on relations between insulin resistance, LDL cholesterol and carotid IMT in healthy adults 29
Different insulin concentrations in resuspended vs. unsuspended NPH insulin: Practical aspects of subcutaneous injection in patients with diabetes. 29
Prevention and Management of Severe Hypoglycemia and Hypoglycemia Unawareness: Incorporating Sensor Technology 29
Physical activity and insulin sensitivity: the RISC study 28
From Metabolic Normality to Cardiometabolic Risk Factors in Subjects With Obesity 28
Female Sex and Angiotensin-Converting Enzyme (ACE) Insertion/Deletion Polymorphism Amplify the Effects of Adiposity on Blood Pressure 28
Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial 26
Human Na + myo-inositol cotransporter gene: alternate spicing generates diverse transcripts 26
Real-time continuous glucose monitoring decreases the risk of severe hypoglycemia in people with type 1 diabetes and impaired awareness of hypoglycemia 26
Impact of patient and treatment characteristics on glycemic control and hypoglycemia in patients with type 2 diabetes initiated to insulin glargine or NPH: A post hoc, pooled, patient-level analysis of 6 randomized controlled trials 26
How to accurately establish pharmacokinetics/ pharmacodynamics of long- Acting insulins in humans: Relevance to biosimilar insulins 25
Switching from insulin bolus treatment to GLP-1 RAs added to continued basal insulin in people with type 2 diabetes on basal-bolus insulin 25
L’insulina biosimilare è “clinicamente uguale” all’originator, ma… 24
Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type 1 diabetes mellitus given meal-time lispro insulin 24
Ipoglicemia: implicazioni cliniche e impatto sulla salute 24
Gli Analoghi dell’Insulina ad Azione Ritardo: dalla storia di ieri alle opzioni di oggi 23
Shape of the OGTT glucose curve and risk of impaired glucose metabolism in the EGIR-RISC cohort 23
Metabolic effects of an SGLT2 inhibitor (Dapagliflozin) during a period of acute insulin withdrawal and development of ketoacidosis in people with type 1 diabetes. Diabetes care 2020;43:2128– 2136 23
Glucagon as a therapeutic approach to severe hypoglycemia: After 100 years, is it still the antidote of insulin? 23
Modification and validation of the triglyceride-to-HDL cholesterol ratio as a surrogate of insulin sensitivity in white juveniles and adults without diabetes mellitus: The single point insulin sensitivity estimator (SPISE) 22
Ipoglicemia: Implicazioni cliniche e impatto sulla salute 21
Totale 4.523
Salva come PNG Salva come JPEG
Categoria #
all - tutte 22.004
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 22.004
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020241 0 0 0 6 43 13 45 5 55 36 9 29
2020/2021818 5 49 41 44 247 71 49 13 96 37 64 102
2021/2022839 20 156 21 59 20 14 8 271 17 25 102 126
2022/20231.510 116 287 17 126 115 191 2 69 527 6 43 11
2023/2024658 36 76 35 11 5 7 121 2 44 28 147 146
2024/2025229 25 157 45 2 0 0 0 0 0 0 0 0
Totale 4.798